Effect of process parameters on the recrystallization and size control of puerarin using the supercritical fluid antisolvent process

Asian Journal of Pharmaceutical Sciences

Volumn 11, Issue 2, 2016, Pages 281-291

  Li, Ying ^a,b   Yu, Yibin ^c   Wang, Hanbing ^c   Zhao, Fengguang ^d  

^a Shenzhen University   (China)

^b TSINGHUA UNIVERSITY   (China)

^c SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^d Research Institute   (China)

Author keywords

Crystallization; GAS; Microparticles; Particle size; Puerarin; Supercritical fluid

Indexed keywords

CARBON DIOXIDE; METHANOL; PUERARIN;

ARTICLE; CONCENTRATION (PARAMETERS); CRYSTAL STRUCTURE; CRYSTALLIZATION; MORPHOLOGY; PARTICLE SIZE; PRESSURE; PROCESSING; SCANNING ELECTRON MICROSCOPY; SOLVENT EFFECT; SUPERCRITICAL FLUID; SUPERCRITICAL FLUID ANTISOLVENT PROCESS; TEMPERATURE;

EID: 84962486735     PISSN: 18180876     EISSN: 2221285X     Source Type: Journal    
DOI: 10.1016/j.ajps.2015.12.001     Document Type: Article

References (29)

1. Perrut M., Jung J., Leboeuf F. Enhancement of dissolution rate of poorly-soluble active ingredients by supercritical fluid processes. Part I: micronization of neat particles. Int J Pharm 2005, 288:3-10.
2. Pasquali I., Bettini R., Giordano F. Supercritical fluid technologies: An innovative approach for manipulating the solid-state of pharmaceuticals. Adv Drug Deliver Rev 2008, 60:399-410.
3. Yadav A.V., Yadav V.B. Pharmaceutical application of supercritical fluid technique: An overview. J Pharm Res 2009, 2:31-44.
4. Chingunpitak J., Puttipipatkhachorn S. Micronization of dihydroartemisinin by rapid expansion of supercritical solutions. Drug Dev Ind Pharm 2008, 34:609-617.
5. Kim M.S., Jin S.J., Kim J.S., et al. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm 2008, 69:454-465.
6. Kim Y.H., Shin K.S. Supercritical fluid-micronized ipratropium bromide for pulmonary drug delivery. Powder Technol 2008, 182:25-32.
7. Kim Y.H., Sioutas C., Shing K.S. Influence of stabilizers on the physicochemical characteristics of inhaled insulin powders produced by supercritical antisolvent process. Pharm Res 2009, 26:61-71.
8. Bakhbakhi Y., Charpentier P.A., Rohani S. Experimental study of the GAS process for producing microparticles of beclomethasone-17, 21-dipropionate suitable for pulmonary delivery. Int J Pharm 2006, 309:71-80.
9. Okamoto H., Danjo K. Application of supercritical fluid to preparation of powders of high-molecular weight drugs for inhalation. Adv Drug Deliver Rev 2008, 60:433-446.
10. Mochizuke S., Teramoto A., Yamashita F., et al. Size-controlled recrystallization of fullerene by gas-antisolvent process. J Mater Sci 2010, 45:1588-1594.
11. Bouchard A., Jovanovic N., Hofland G.W., et al. Ways of manipulating the polymorphism of glycine during supercritical fluid crystallization. J Supercit Fluids 2008, 44:422-432.
12. Moribe K., Tozuka Y., Yamamoto K. Supercritical carbon dioxide processing of active pharmaceutical ingredients for polymorphic control and for complex formation. Adv Drug Deliver Rev 2008, 60:328-338.
13. Chen K.X., Zhang X.Y., Pan J. Recrystallization of andrographolide using the supercritical fluid antisolvent process. J Crystal Growth 2005, 274:226-232.
14. Ruan L.P., Chen S., Yu B.Y., et al. Prediction of human absorption of natural compounds by the non-everted rat intestinal sac model. Eur J Med Chem 2006, 41:605-610.
15. Wang J., Ji M., Hua W.Y., et al. Development of puerarin. Prog Pharm Sci 2003, 27:70-73.
16. Li Y., Pan W.S., Chen S.L., et al. Pharmacokinetic, tissue distribution, and excretion of puerarin and puerarin-phospholipid complex in rats. Drug Dev Ind Pharm 2006, 32:413-422.
17. Li Y., Pan W.S., Chen S.L., et al. Studies on preparation of puerarin phytosomes and their solid dispersions. Chin Pharm J 2006, 37:695-697.
18. Pan J., Zhang Y., Yuan C.X. Studies on the polymorphism of puerarin. Chin J Pharm Anal 2004, 24:119-122.
19. Yeo S.D., Kim M.S., Lee J.C. Recrystallization of sulfathiazole and chlorpropamide using the supercritical fluid antisolvent process. J Supercrit Fluids 2003, 25:143-154.
20. Wang H.Y., Zhang L.Z., Zhang M.H. Supercritical antisolvent and the application in pharmaceuticals. Chem Ind Eng Prog 2004, 23:705-709.
21. Fages J., Lochard H., Letourneau J.J., et al. Particle generation for pharmaceutical applications using supercritical fluid technology. Powder Tech 2004, 141:219-226.
22. Park S.J., Yeo S.D. Recrystallization of caffeine using gas antisolvent process. J Supercrit Fluids 2008, 47:85-92.
23. Zhao H.W., Liang Y. Elementary studies of gas antisolvent crystallization technique. Heilongjiang Med J 2003, 16:452-454.
24. Park S.J., Yeo S.D. Antisolvent crystallization of sulfa drugs and the effect of process parameters. Sep Sci Technol 2007, 42:2645-2660.
25. Moneghini M., Kikic I., Voinovich D., et al. Study of solid state of carbamazepine after processing with gas anti-solvent technique. Eur J Pharm Biopharm 2003, 56:281-289.
26. Li Y., Yang D.J., Chen S.L., et al. Comparative physicochemical characterization of phospholipids complex of puerarin formulated by conventional and supercritical methods. Pharm Res 2008, 25:563-577.
27. Li Y., Yang D.J., Zhou W., et al. Recrystallization of puerarin using the supercritical fluid antisolvent process. J Crystal Growth 2012, 340:142-148.
28. Sanganwara G.P., Sathiqari S., Babu R.J., et al. Simultaneous production and co-mixing of microparticles of nevirapine with excipients by supercritical antisolvent method for dissolution enhancement. Eur J Pharm Sci 2010, 39:164-174.
29. Kim M.S., Lee S., Park J.S., et al. Micronization of cilostazol using supercritical antisolvent process: effect of process parameters. Powder Technol 2007, 177:64-70.